ONCOLYTIC ACTIVITY OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
DOI:
https://doi.org/10.15407/exp-oncology.2024.02.081Keywords:
RSV, oncolytic virotherapy, oncolytic viruses, immunotherapy, immune activation, tumors.Abstract
Oncolytic viruses (OVs) are emerging as novel tools in cancer therapy. Oncolytic virotherapy offers an attractive therapeutic combination of tumor-specific killing and immune co-stimulation, therefore amplifying the host immune response against tumors. Moreover, OVs can be engineered for the expression of different immunostimulatory molecules to optimize and enhance the efficacy of oncolytic virotherapy. The effectiveness of OVs has been demonstrated in many preclinical studies for different types of cancers to achieve the aim of personalized cancer therapy. Human respiratory syncytial virus (RSV), an RNA virus of the Pneumoviridae family causes severe lower respiratory tract infections in infants and immunocompromised individuals. Interestingly, the oncolytic activity of RSV demonstrated in human prostate, hepatocellular, and dermal cancer cells is mostly mediated via apoptotic cell death associated with the impaired NF-κB activation or with the defect of the IFNα/β-induced STAT-1 activation. At the same time, the studies on cervical cancer revealed that RSV infection resulted in autophagy activation and apoptosis through the ROS-BAX and TNF- α-mediated pathways. The rational combinations of OVs, including RSV, with other approaches may benefit patients whose response to conventional therapies is limited. Here, we discuss the oncolytic activity of RSV and its potential use against different types of cancer.
References
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-662. https://doi.org/10.1038/nrd4663
Chulpanova DS, Solovyeva VV, Kitaeva KV, et al. Recombinant viruses for cancer therapy. Biomedicines. 2018;6(4):94. https://doi.org/10.3390/biomedicines6040094
Bhat R, Rommelaere J. Emerging role of natural killer cells in oncolytic virotherapy. ImmunoTargets Ther. 2015;4:65- 77. https://doi.org/10.2147/ITT.S55549
Cao GD. The oncolytic virus in cancer diagnosis and treatment. Front Oncol. 2020;10:1786. https://doi.org/10.3389/ fonc.2020.01786
Martin NT, Bell JC. Oncolytic virus combination therapy: killing one bird with two stones. Mol Ther. 2018;26(6):1414- 1422. https://doi.org/10.1016/j.ymthe.2018.04.001
Fu LQ. Recent advances in oncolytic virus-based cancer therapy. Virus Res. 2019;270:197675. https://doi.org/10.1016/j. virusres.2019.197675
Echchgadda I. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer. 2011;11:43. https://doi. org/10.1186/1471-2407-11-43
Salimi V. The oncolytic effect of respiratory syncytial virus (rsv) in human skin cancer cell line, A431. Iran Red Cres- cent Med J. 2013;15(1):62-67. https://doi.org/10.5812/ircmj.4722
Afonso CL. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. 2016;161(8):2351-2360. https://doi. org/10.1007/s00705-016-2880-1
Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331-379. https://doi.org/10.1007/s12016-013-8368-9
O'Donnell DR, Milligan L, Stark JM. Induction of CD95 (Fas) and apoptosis in respiratory epithelial cell cultures fol- lowing respiratory syncytial virus infection. Virology. 1999;257(1):198-207. https://doi.org/10.1006/viro.1999.9650
Bitko V, Barik S. An endoplasmic reticulum-specific stress-activated caspase (caspase-12) is implicated in the apoptosis of A549 epithelial cells by respiratory syncytial virus. J Cell Biochem. 2001;80(3):441-454. https://doi. org/10.1002/1097-4644(20010301)80:3
Echchgadda I. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 2009;16(12):923-935. https://doi.org/10.1038/cgt.2009.34
Samadi M. The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms. BMC Cancer. 2023;23(1):1-12. https://doi.org/10.1186/s12885-023-11326-y
Eckardt-Michel J, Lorek M, Baxmann D, et al. The fusion protein of respiratory syncytial virus triggers p53-depen- dent apoptosis. J Virol. 2008;82(7):3236-3249. https://doi.org/10.1128/JVI.01887-07
Kotelkin A, Prikhod'ko EA, Cohen JI, et al. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol. 2003;77(17):9156-9172. https://doi.org/10.1128/ jvi.77.17.9156-9172.2003
Choi SH, Park BK, Lee KW, et al. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell- lines. BMB Rep. 2015;48(10):565-570. https://doi.org/10.5483/bmbrep.2015.48.10.268
Aziz IM, Bhat R, Farrag MA, Almajhdi FN. Oncolytic activity of human orthopneumovirus in cancer cell lines. Exp Oncol. 2022;44(2):113-120. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.18084
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.